BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect. Autolus attributed the decision to let the option expire to BioNTech’s pipeline prioritization. Source: Fierce Biotech 20/3/2025